Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)

Inclusion Criteria:

- Participant provides signed informed consent prior to the initiation of any study
assessments

- Has laboratory-confirmed SARS-CoV-2 Infection as determined by nucleic acid
amplification test, polymerase chain reaction, antigen test or other commercial or
public health assay (based on locally acceptable accepted guidelines) in a sample
collected less than (<)10 days prior to randomization

- Has chest imaging consistent with COVID-19 pneumonia (as per locally accepted
guidelines) If chest imaging is not available during Screening, please discuss with
Medical Monitor or designee regarding evidence of probable COVID-19 pneumonia for
study participant eligibility

- Not on mechanical ventilation or ECMO

- Has an SpO2 less than (<) 94 percent in room air And able to maintain a partial
pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) greater than or equal to
(>=) 150 (Or equivalent SpO2/FiO2 >=190) with a maximum FiO2 0.4 if participant is on
chronic low oxygen therapy (less than or equal to 2 Liter), assess their current
baseline oxygen requirements for eligibility

- Requires hospitalization

- Other protocol defined inclusion criteria may apply

Exclusion Criteria:

- Any condition that could interfere with the study objectives, conduct or evaluation in
the opinion of the Investigator or Sponsor or designee

- Significantly uncontrolled medical illness (eg, cardiovascular disease, hypertension,
diabetes mellitus, obstructive lung disease, neurological associated with seizures
(example: cerebrovascular accident/stroke, acute brain infection, traumatic brain
injury, progressive brain disease, congenital brain disease or neuropsychiatric
disorder)

- Known active infection other than COVID-19

- Pregnancy or Breastfeeding

- Other protocol defined exclusion criteria may apply